ReviewTransfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie2026
Extended Half-Life Factor Concentrates in Haemophilia Treatment.
Review in Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Haemophilia: Novel Therapies and Diagnostic Challenges.Transfusion medicine and hemotherapy : offizielles Organ der Deutschen Gesellschaft fur Transfusionsmedizin und Immunhamatologie · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: For prevention of musculoskeletal bleeds in patients with severe and moderate haemophilia A (HA) or B (HB), prophylaxis is recommended. Clotting factor concentrates with standard half-life (SHL) necessitate frequent infusions associated with high treatment burden, leading to the development of extended half-life (EHL) factor concentrates and non-factor therapies (NFT). Summary: This review aimed to summarize knowledge on EHL for HA and HB. Those employ fragment crystallizable fusion, albumin fusion or PEGylation to extend half-life and reduce clearance. Half-life extension for factor VIII (FVIII) has been limited due to binding to and elimination with endogenous von Willebrand factor (VWF). With linking the FVIII molecule to a D'D3 domain of the VWF, binding to endogenous VWF is inhibited, enabling the development of a FVIII concentrate with an ultra-long half-life. EHL allows less frequent prophylaxis, and clinical trials and real-world data show reduced ABR, better joint outcomes, improved adherence and better patient-reported health-related quality of life. Inhibitor rates in previously treated patients are very low and seem to be similar or lower compared to SHL recombinant FVIII (rFVIII) in previously untreated patients, but robust head-to-head comparative data are limited. Close monitoring remains essential. For PEG-containing products, extensive non-clinical and clinical experience has not identified clear PEG-related organ toxicity in humans Key Messages: EHL enables efficacious and safe prophylaxis as well as bleed treatment with the possibility of individualization. With improved ABRs, joint health and low treatment burden, they prove clinical benefit compared to SHL and coexist with NFT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.